Risk-adapted treatment for metastatic prostate cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial looks at whether treatment for metastatic prostate cancer can be tailored to each patient's risk level, potentially using less intensive therapy for lower-risk disease. It aims to maintain effectiveness while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of the body and has not been treated with hormone therapy before.
- You have not had chemotherapy (other than docetaxel) for prostate cancer in the past.
- You have not received radiation therapy within the last 2 weeks.
- You have not taken certain hormone therapy pills for non-metastatic prostate cancer within the last 6 months.
- You can swallow oral medications and are willing to follow the treatment plan.
- You do not have leptomeningeal disease (cancer spread to the membranes around the brain and spinal cord).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial tests a combination of precise radiation therapy (SBRT) and a drug called darolutamide for men whose prostate cancer has spread to a limited number of other parts of the body. The goal is to see if this approach can control the cancer effectively with fewer side effects.
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
This study tests two different combinations of drugs for men with prostate cancer that has spread to other parts of the body but still responds to hormone therapy. It compares a new pill (tulmimetostat) combined with standard treatments like darolutamide or abiraterone to see if it can help control the cancer longer.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.